BrainsWay Ltd. announced the formation of a strategic partnership with a prominent mental health clinical treatment provider with an increasingly expanding footprint in the Northeast region of the United States. As a result of this partnership and a series of successive orders, a total of 10 Deep Transcranial Magnetic Stimulation (Deep TMS) systems will be installed by this provider in 2023 alone, with the potential for additional systems thereafter.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,067 ILa | -1.84% | -1.20% | -7.14% |
05-09 | Oppenheimer Adjusts Brainsway Price Target to $11 From $10, Maintains Outperform Rating | MT |
05-09 | HC Wainwright Adjusts Price Target on Brainsway to $15 From $13, Keeps Buy Rating | MT |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-7.14% | 95.3M | |
+11.07% | 221B | |
+9.65% | 186B | |
+14.86% | 137B | |
+28.07% | 109B | |
-0.42% | 63.09B | |
+15.00% | 52.68B | |
+4.86% | 50.86B | |
+9.57% | 42.53B | |
+7.35% | 37.76B |
- Stock Market
- Equities
- BWAY Stock
- News BrainsWay Ltd.
- Brainsway Ltd. Forges Strategic Partnership with Treatment Provider in Northeast U.S